Please use this identifier to cite or link to this item:
|Title:||Growth hormone for risk stratification and effects of therapy in acute myocardial infarction|
|Authors:||Ng, Leong Loke|
Bhandari, Sanjay S.
Sandhu, Jatinderpal K.
Quinn, Paulene A.
Squire, Iain B.
Davies, Joan E.
Jones, Donald J.
|Publisher:||Taylor & Francis : STM, Behavioural Science and Public Health Titles|
|Citation:||Biomarkers, 2015, 20 (6-7), pp. 371-375|
|Abstract:||CONTEXT: Excess growth hormone (GH) is associated with early mortality. OBJECTIVES: We assessed the association of GH with prognosis after acute myocardial infarction (AMI), and the effects of secondary prevention therapies. METHODS: GH was measured using a high-sensitivity assay in 953 AMI patients (687 males, mean age 66.1 ± 12.8 years). RESULTS: During 2 years follow-up, there were 281 major adverse cardiac events (MACE). Patients with MACE had higher GH levels (median [range], 0.91 [0.04-26.28] μg/L) compared to event-free survivors (0.59 [0.02-21.6], p < 0.0005). In multivariate Cox survival analysis, GH was a significant predictor of MACE (hazard ratios 1.43, p = 0.026 and 1.49, p = 0.01, respectively) with significant interactions with beta blocker therapy (p = 0.047) and angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE/ARB) therapy (p = 0.016). CONCLUSIONS: GH levels post-AMI are prognostic for MACE and may indicate those patients who benefit from beta blocker and ACE/ARB therapy.|
|Embargo on file until:||2-Nov-2016|
|Rights:||Copyright © 2015, Taylor & Francis. All rights reserved. This is an Accepted Manuscript of an article published by Taylor & Francis in Biomarkers on 2 Nov 2015, available online: http://www.tandfonline.com/doi/abs/10.3109/1354750X.2015.1093031|
|Description:||The file associated with this record is under a 12-month embargo from publication in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.|
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Files in This Item:
|GHinAMI2015_Biomarkers.docx||Post-review (final submitted)||206.5 kB||Unknown||View/Open|
|GHinAMI2015_Biomarkers.pdf||Post-review (final submitted)||415.42 kB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.